NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress<
24 Mar 2025

Positive Data from Phase 1 Trial of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) Presented at the 40th Annual European Association of Urology Congress

Data Supports Potential for a Paradigm Shifting Approach in the Front-Line Treatment of patients with NMIBC
Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock<
18 Mar 2025

Mineralys Therapeutics Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Aggregate gross proceeds to Mineralys from the offering were approximately $201.2M
SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease<
13 Mar 2025

SpliceBio Announces First Patient Dosed in Phase 1/2 ASTRA Study of SB-007, a Dual-AAV Gene Therapy for Stargardt Disease

SB-007 addresses the root cause of Stargardt disease with the potential to treat all patients across all ABCA4 mutations
Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology<
11 Mar 2025

Xeltis expands Medical Advisory Board with World Leading Experts in Clinical Nephrology

Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement
Mineralys Therapeutics Announces Proposed Public Offering of Common Stock<
11 Mar 2025

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Underwritten public offering of $250.0 million of shares of its common stock
Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension<
10 Mar 2025

Mineralys Therapeutics Announces Positive Topline Results from Launch-HTN and Advance-HTN Pivotal Trials of Lorundrostat for the Treatment of Uncontrolled or Resistant Hypertension

Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trial
NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology<
06 Mar 2025

NorthSea Therapeutics Announces Publication of Positive Results from Phase 2b ICONA Clinical Trial of Icosabutate in Biopsy-Confirmed F1-F3 MASH in Journal of Hepatology

Positive results support advancement of icosabutate into further clinical development in MASH patients
MedLumics® Announces the Publication of FIM Results for the AblaView® (PF) Ablation System in (AF) Patients, Including Clinical Safety and Our Ability to Predict Durable Lesions at 3 Months With 100% Specificity<
05 Mar 2025

MedLumics® Announces the Publication of FIM Results for the AblaView® (PF) Ablation System in (AF) Patients, Including Clinical Safety and Our Ability to Predict Durable Lesions at 3 Months With 100% Specificity

Significant advancement toward more precise, safer, and more effective treatments for patients.
Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett’s Syndrome (TREE study)<
05 Mar 2025

Minoryx announces dosing of the first patient with leriglitazone in the phase 2a study in Rett’s Syndrome (TREE study)

The results from the TREE study are expected during the first half of 2026
SparingVision appoints Anjeza Gjino as Chief Financial Officer<
03 Mar 2025

SparingVision appoints Anjeza Gjino as Chief Financial Officer

Anjeza’s proven track-record and experience in scaling-up and financing biotech companies will be invaluable to SparingVision.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.